PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+15.75%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.89B
AUM Growth
+$1.89B
(+15%)
Cap. Flow
-$4.11M
Cap. Flow
% of AUM
-0.22%
Top 10 Holdings %
Top 10 Hldgs %
39.85%
Holding
93
New
19
Increased
21
Reduced
14
Closed
17
Top Buys
| 1 |
Outset Medical
OM
|
$131M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$41.4M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$29.8M |
| 4 |
Avantor
AVTR
|
$28.6M |
| 5 |
Gilead Sciences
GILD
|
$25.6M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$156M |
| 2 |
McKesson
MCK
|
$50.5M |
| 3 |
Cardinal Health
CAH
|
$45.2M |
| 4 |
Labcorp
LH
|
$31.4M |
| 5 |
Baxter International
BAX
|
$25.4M |
Sector Composition
| 1 | Healthcare | 77.72% |
| 2 | Technology | 5.64% |
| 3 | Consumer Discretionary | 1.62% |
| 4 | Industrials | 0.9% |
| 5 | Utilities | 0.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Outset Medical
OM
$247M
| $131M | 6.04% | +2,872,990 | New | +$131M |
|
|
IMMU
2
DELISTED
Immunomedics Inc
IMMU
| $114M | 5.28% | 1,343,570 -1,835,404 | -58% | -$156M |
|
|
HZNP
3
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $106M | 4.88% | 1,359,420 +216,942 | +19% | +$16.9M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals Inc
ALXN
| $80.5M | 3.72% | 703,817 +24,933 | +4% | +$2.85M |
|
|
5
Gilead Sciences
GILD
$140B
| $68.1M | 3.15% | 1,078,089 +404,677 | +60% | +$25.6M |
|
6
ICU Medical
ICUI
$3.15B
| $55.4M | 2.56% | 302,999 +77,448 | +34% | +$14.2M |
|
7
IQVIA
IQV
$32.4B
| $53.3M | 2.46% | 337,987 +50,449 | +18% | +$7.95M |
|
8
BioMarin Pharmaceuticals
BMRN
$11.2B
| $53.3M | 2.46% | 700,052 +216,973 | +45% | +$16.5M |
|
9
Penumbra
PEN
$10.6B
| $46.5M | 2.15% | 239,397 +128,095 | +115% | +$24.9M |
|
10
HCA Healthcare
HCA
$94.5B
| $45.5M | 2.1% | 364,940 +35,583 | +11% | +$4.44M |
|
|
NVRO
11
DELISTED
NEVRO CORP.
NVRO
| $44.3M | 2.05% | 318,232 +214,052 | +205% | +$29.8M |
|
12
AbbVie
ABBV
$372B
| $43.9M | 2.03% | 501,750 -142,838 | -22% | -$12.5M |
|
13
Arcus Biosciences
RCUS
$1.13B
| $43.5M | 2.01% | 2,536,932 +801,351 | +46% | +$13.7M |
|
|
MRTX
14
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $41.4M | 1.91% | +249,068 | New | +$41.4M |
|
15
iRhythm Technologies
IRTC
$5.46B
| $39.8M | 1.84% | 167,008 -81,550 | -33% | -$19.4M |
|
16
Edwards Lifesciences
EW
$47.8B
| $38.9M | 1.8% | 487,842 +94,407 | +24% | +$7.54M |
|
17
Danaher
DHR
$147B
| $35.2M | 1.63% | 163,663 -8,658 | -5% | -$1.86M |
|
18
Humana
HUM
$36.5B
| $32.2M | 1.49% | 77,740 -8,280 | -10% | -$3.43M |
|
19
Molina Healthcare
MOH
$9.8B
| $29.7M | 1.38% | 162,524 +69,356 | +74% | +$12.7M |
|
|
XYZ
20
Block, Inc.
XYZ
$48.5B
| $29.5M | 1.36% | 181,509 | – | – |
|
|
PPD
21
DELISTED
PPD, Inc. Common Stock
PPD
| $29.1M | 1.35% | 787,863 -285,628 | -27% | -$10.6M |
|
|
22
Avantor
AVTR
$9.18B
| $28.6M | 1.32% | +1,270,070 | New | +$28.6M |
|
23
Elevance Health
ELV
$71.8B
| $27.8M | 1.28% | 103,455 +3,455 | +3% | +$928K |
|
24
Heron Therapeutics
HRTX
$207M
| $27.7M | 1.28% | 1,872,012 -359,390 | -16% | -$5.33M |
|
|
25
Labcorp
LH
$23.1B
| $27M | 1.25% | 143,323 -167,007 | -54% | -$31.4M |
|